Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
interferon-beta + nimustine
- Development stage
- Unknown
- Lead developer
- Biogen
- Modality
- Small Molecules
- Administration
- Intramuscular, Intravenous, Subcutaneous
01
Overview
A combination therapy consisting of interferon-beta (IFN-beta), a cytokine with immunomodulatory properties, and nimustine (ACNU), a nitrosourea alkylating agent that crosses the blood-brain barrier. This combination is primarily used in the treatment of malignant gliomas, particularly glioblastoma multiforme, often administered alongside radiation therapy.
- Other names
- IFN-beta + ACNU
02
Targets
DNAIFNAR2 (Interferon alpha/beta receptor subunit 2)IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on interferon-beta + nimustine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on interferon-beta + nimustine.